Department of Obstetrics, Shimane University School of Medicine, Shimane, Japan.
Anticancer Res. 2012 Aug;32(8):3091-5.
Recently we reported that amplification of the Zinc Finger Protein 217 (ZNF217) gene adversely affects survival of patients with ovarian clear cell carcinoma. This study sought to determine the mechanism by which ZNF217 amplification affects patient survival.
Fluorescence in situ hybridization (FISH) was used to detect ZNF217 gene amplification status and ZNF217-specific siRNA was used to inactivate ZNF217 for in vitro biological analyses.
We found ZNF217 gene amplification to be significantly correlated with lymph node metastasis (p<0.05) in ovarian clear cell carcinoma. Profound inhibition of cell migration and invasion was observed in siRNA-treated cells with ZNF217 amplification, compared to cells without amplification.
These findings provide new insight into the biological role of ZNF217 gene amplification in ovarian clear cell carcinoma. Additionally, our observations have an important therapeutic implication for patients with ovarian clear cell carcinomas with ZNF217 amplification, as these patients may potentially benefit from ZNF217 targeted-therapy.
最近我们报道了锌指蛋白 217(ZNF217)基因扩增对卵巢透明细胞癌患者的生存不利。本研究旨在确定 ZNF217 扩增影响患者生存的机制。
采用荧光原位杂交(FISH)检测 ZNF217 基因扩增状态,并用 ZNF217 特异性 siRNA 灭活 ZNF217 进行体外生物学分析。
我们发现 ZNF217 基因扩增与卵巢透明细胞癌的淋巴结转移显著相关(p<0.05)。与未扩增的细胞相比,在有 ZNF217 扩增的 siRNA 处理的细胞中,观察到细胞迁移和侵袭的显著抑制。
这些发现为 ZNF217 基因扩增在卵巢透明细胞癌中的生物学作用提供了新的见解。此外,我们的观察结果对 ZNF217 扩增的卵巢透明细胞癌患者具有重要的治疗意义,因为这些患者可能从 ZNF217 靶向治疗中受益。